Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06712745 · ClinicalTrials.gov registry record · Early Phase 1
Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung
A Early Phase 1 study of Metastasis and Cancer, Lung, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06712745: Recruiting Early Phase 1 study of Metastasis and Cancer, Lung, sponsored by University of Texas Southwestern Medical Center.
NCT06712745 is a Early Phase 1 study of Metastasis and Cancer, Lung that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 30 participants, below the 92-participant average among 15 other Metastasis trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06712745, a Early Phase 1 study of Metastasis and Cancer, Lung, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to enhance the safety profile of SAbR in ultra-central tumors of the lung (primary or metastatic) without compromising its effectiveness.
Primary Outcome
Rates of overall response will be assessed by RECIST criteria.Efficacy will be compared between PULSAR and historical controls from HILUS using ANOVA and chi-square test. Kaplan-Meier methods will be used to estimate progression-free survival, time to subsequent SABR, overall survival, clinical benefit rate, time to treatment discontinuation, duration of response, and time to new metastases. Response duration will be summarized for patients who responded. Descriptive summary statistics such as
Conditions Studied
Interventions
- RADIATION Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR)
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-19 |
| Est. Completion | 2028-12 |
| Phase | Early Phase 1 |
What NCT06712745 shows while recruiting
NCT06712745 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 92-participant average among 15 other Metastasis trials with a reported enrollment target (67% lower).
The record links to 2 conditions, with Metastasis appearing as the primary indexed condition, and to 1 intervention - of which Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR) is the first listed.
NCT06712745 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06712745 about?
NCT06712745 is a clinical study titled "Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung". The objective of this study is to enhance the safety profile of SAbR in ultra-central tumors of the lung (primary or metastatic) without compromising its effectiveness.
What is the current status of trial NCT06712745?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-09-19. Estimated completion is 2028-12.
What conditions does trial NCT06712745 study?
This clinical trial studies the following conditions: Metastasis, Cancer, Lung.
What interventions are being tested in trial NCT06712745?
The interventions under investigation include: Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR) (RADIATION).
Who is sponsoring clinical trial NCT06712745?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06712745 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06712745's enrollment target sits among peer trials
30 12th of 15 higher than 4 of 15 other Metastasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
-
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
RECRUITING · Phase 1
-
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
RECRUITING · Phase 2
-
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI